339 pharmaceutical companies reported half-yearly results, and five reported net profits of more than $2 billion

As of September 1, 339 A-share pharmaceutical companies have disclosed their results for the first half of 2020.
Overall, because of the impact of the epidemic, more than 50% of the first quarter of the enterprise performance (revenue, net profit) fell, 53 net profit losses;
, it is worth mentioning that in the first half of the year, 16 pharmaceutical companies had revenues of more than 10 billion yuan, and five pharmaceutical companies had net profits of more than 2 billion yuan.
Meirui Medical: Net profit of 3.454 billion yuan August 27, Meirui Medical released a semi-annual results report that the first half of 2020 attributable to shareholders of listed companies net income of about 3.454 billion yuan, up 45.78 percent year-on-year, operating income of about 10.564 billion yuan, up 28.75 percent year-on-year, underlying earnings per share of about 2.84 percent, up 45.78 percent year-on-year.
said the big increase in first-half results was mainly due to the outbreak driving demand for reagents, portable ultrasound and mobile DR, which led to overall growth in the in-body diagnostics and medical imaging business. in the second half of
, in the case of the epidemic, the company will continue to focus on the main industry, strengthen product research and development innovation, domestic and international marketing expansion and localization of the construction of a comprehensive capacity, expand the customer base breakthrough results, continue to improve the company's product market share;
Hengrui Pharmaceuticals: Net profit of 2.662 billion yuan on July 31, Hengrui Pharmaceuticals announced 2020 in-year report: revenue during the reporting period of 11.309 billion yuan, up 12.79 percent year-on-year, home net profit of 2.662 billion yuan, up 10.34 percent year-on-year, net profit after non-recurring home, 2.562 billion yuan, up 11.94 percent year-on-year.
fact, in the eyes of the industry, Hengrui Pharmaceutical in accordance with the development of recent years performance growth should be between 20-30%, the reason for not meeting expectations is mainly the impact of the epidemic, Q1 growth has slowed down.
but after a brief adjustment, Q2 performance improved slightly.
industry expects that, as Hengrui Pharmaceuticals' innovative drugs gradually enter the harvest period, Karelliju, Apatini, pyridoxine, etc. may be expected to expand and thicken their performance with health insurance and adaptive disorders.
Yunnan White Pharmaceuticals: Net profit of 2.454 billion yuan On August 28, Yunnan White Pharmaceuticals released its semi-annual results report, reporting that net profit attributable to shareholders of listed companies in the first half of 2020 was about 2.454 billion yuan, up 9.2% YoY, and operating income was about 15.493 billion yuan, up 11.48% YoY, with underlying earnings per share of 1.92 billion yuan, up 9.2% YoY.
Yunnan White Medicine said that with the stable control of the domestic epidemic, the company's production and business activities gradually on the right track, but the future by the global spread of the epidemic, there is still some uncertainty.
the new global situation and economic situation, the company will increase the adjustment of product structure according to market demand, marketing model changes, as far as possible to minimize the impact of the outbreak on the company's sales and operating performance.
: Net profit of 2.443 billion yuan on August 27, Shanghai Pharmaceuticals released its 2020 half-yearly report.
company achieved operating income of 87.165 billion yuan in the first half of the year, of which the pharmaceutical industry achieved revenue of 11.675 billion yuan and pharmaceutical business revenue of 75.490 billion yuan.
, net profit attributable to the parent company was RMB2.443 billion, up 6.84 percent year-on-year.
report, the Shanghai pharmaceutical industry sector bucked the trend in the first half of the year.
that this is mainly due to the company's forward-looking strategy and market dynamics of the tactics. During the
reporting period, Shanghai Pharmaceuticals further optimized and clarified the development path of the three major sectors of innovative medicine, generic drugs and traditional Chinese medicine, and launched a number of major projects, including biomedical innovation incubation and pilot industrialization "one-stop" public service platform, green quality api base, bioantibodies and ADC drug research and development pilot and industrialization base.
Xin and Cheng: Net profit of 2.212 billion yuan On June 23, Xinhecheng released its earnings forecast that in the first half of 2020, the company expects to achieve a net profit of 2.196 billion yuan to 2.311 billion yuan, up 90% to 100% YoY.
, according to the announcement, the main reason for the increase in performance is the company's vitamin A, vitamin E, biotin and other products sales prices and sales volume increased year-on-year.
understood that at present, Xin and Cheng are actively exploring shandong and Heilongjiang base, deep layout nutrition business, involving new varieties including VB2/VC/VB6/VB12 and so on.
, methionine production capacity will be increased from 50,000 tons to 300,000 tons, methionine business will also become another pillar of the company's nutrition sector.
industry expects that the future of new and growing outstanding, multi-business layout is expected to further enable it to further grow into a global fine chemical guide.